SCHEMBL11948423

SCHEMBL11948423

CCn1c2ccccc2c2cc(N(CC(=O)OC)S(=O)(=O)c3cc(Cl)cc(Cl)c3)ccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.46
PKM P14618 1/20 0.45
HSD17B10 Q99714 1/20 0.45
NPY5R Q15761 2/20 0.44
NR1I2 O75469 1/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 4/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
RORC P51449 4/20 0.43
NPSR1 Q6W5P4 1/20 0.43
PTGDR2 Q9Y5Y4 1/20 0.41
KDM4E B2RXH2 3/20 0.41
LMNA P02545 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
RAB9A P51151 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HCRTR1 O43613 1/20 0.41
HPGD P15428 1/20 0.41
PAX8 Q06710 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2846847 0.89 PTGDR2 (0.48) NPY5RRORCNPSR1PTGDR2KDM4E
SCHEMBL2844877 0.85 KEAP1 (0.47) MAPTMEN1KMT2ANPSR1KDM4E
SCHEMBL11948421 0.85 KDM4E (0.42) NPY5RMAPTMEN1KMT2ANPSR1
SCHEMBL2847940 0.83 PTGDR2 (0.44) NPY5RRORCPTGDR2KDM4ELMNA
SCHEMBL11948427 0.81 PTGDR2 (0.38) NPY5RMAPTMEN1KMT2ARORC
SCHEMBL11948418 0.81 NPY5R (0.41) NPY5RRORCNPSR1PTGDR2KDM4E
SCHEMBL2852645 0.81 PTGDR2 (0.42) NPY5RRORCNPSR1PTGDR2KDM4E
SCHEMBL2848047 0.81 PTGDR2 (0.43) NPY5RMAPTMEN1KMT2ANPSR1
SCHEMBL11948480 0.80 RORC (0.36) NPY5RMAPTMEN1KMT2ARORC
SCHEMBL2845666 0.80 PTGDR2 (0.46) NPY5RMAPTKMT2ARORCNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232312-B2 Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-07-31 US disclosed
US-8232312-B2 Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-07-31 US disclosed
US-20100130557-A1 SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-05-27 US disclosed
US-20100130557-A1 SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-05-27 US disclosed
WO-2008113760-A2 ARYLSULPHONYGLYCINE DERIVATIVES AS SUPPRESSORS OF THE INTERACTION OF GLYCOGEN PHOSPHORYLASE A WITH THE GL SUBUNIT OF GLYCOGEN-ASSOCIATED PROTEIN PHOSPHATASE 1 (PPL) FOR THE TREATMENT OF METABOLIC DISORDERS, PARTICULARY DIABETES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130557-A1 SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS PYGL, PYGM, G6PC1 TSHR 2641/4885PKM 144/4885HSD17B10 1903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.